Compare DLPN & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLPN | EDSA |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | Canada |
| Employees | 269 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 12.8M |
| IPO Year | N/A | N/A |
| Metric | DLPN | EDSA |
|---|---|---|
| Price | $1.51 | $1.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 35.8K | 32.3K |
| Earning Date | 11-12-2025 | 12-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $53,371,115.00 | N/A |
| Revenue This Year | $10.62 | N/A |
| Revenue Next Year | $13.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.86 | N/A |
| 52 Week Low | $0.75 | $1.44 |
| 52 Week High | $1.88 | $4.49 |
| Indicator | DLPN | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 39.42 | 30.99 |
| Support Level | $1.44 | $1.44 |
| Resistance Level | $1.65 | $1.54 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 18.18 | 9.03 |
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.